The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
(Adds background, details on device withdrawal, BSX comment)
April 16 (Reuters) - The U.S. Food and Drug Administration on Tuesday ordered makers of transvaginal surgical mesh implants to immediately stop sale and distribution of the products in the United States.
The FDA said makers of the products such as Boston Scientific Corp and Coloplast A/S did not demonstrate a reasonable assurance of safety and effectiveness of these devices in their premarket applications.
The devices, made of synthetic or biological material, are commonly implanted in women to repair weakened or damaged tissue and provide support in cases of pelvic organ prolapse (POP).
The prolapse occurs when the muscles and tissues supporting the pelvic organs - the uterus, bladder, or rectum - become weak or loose, resulting in one or more of the pelvic organs to drop or press into or out of the vagina.
In 2016, the agency had reclassified the mesh as class III or high risk, requiring its makers to submit and obtain approval from the FDA's most stringent device review pathway in order to continue marketing the products.
The companies will now have 10 days to submit their plan to withdraw these products from the market, the agency said in a statement https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm636114.htm.
Boston Scientific said it was "deeply disappointed" by the FDA's decision and will work with the agency to determine the next steps.
"The inaccessibility of these products will severely limit treatment options for the 50 percent of women in the U.S. who will suffer from pelvic organ prolapse during their lives," the company said in an emailed statement.
Shares of Boston Scientific slumped 4.6 percent $36.04 in afternoon trading.
Coloplast was not immediately available for comment.
The agency also ordered Boston Scientific and Coloplast to continue follow-up of subjects already enrolled in their 522 studies for the mesh.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)